NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis $0.13 -0.01 (-8.19%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$0.13 0.00 (-0.08%) As of 10/16/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Vivos Therapeutics Stock (NASDAQ:VVOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vivos Therapeutics alerts:Sign Up Key Stats Today's Range$0.13▼$0.1450-Day Range$0.13▼$0.3452-Week Range$0.13▼$3.11Volume1.62 million shsAverage Volume5.74 million shsMarket Capitalization$1.82 millionP/E RatioN/ADividend YieldN/APrice Target$2.80Consensus RatingHold Company Overview Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing non-surgical treatments for sleep-related breathing disorders and related craniofacial conditions. The company’s primary focus is obstructive sleep apnea, a disorder in which the upper airway repeatedly narrows or becomes blocked during sleep. The company markets the Vivos System, a series of customized oral appliances designed to help reposition and support the upper airway. Its offerings include the Vivos Complete Airway Repositioning Appliance (CARE) and other dental devices intended to improve airway function during sleep. Vivos provides products and related clinical support through dentists and other trained healthcare professionals, offering an alternative or complement to traditional treatments such as continuous positive airway pressure therapy. Founded in 2016, Vivos Therapeutics is headquartered in Denver, Colorado, and serves patients primarily through a network of trained dental providers in the United States, with international availability developing through its distribution and provider network. Kirk Huntsman has served as the company’s chief executive officer and has been associated with its leadership since its early development. The company’s common stock trades on the Nasdaq under the symbol VVOS.AI Generated. May Contain Errors. Read More Vivos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreVVOS MarketRank™: 2.11518528116 of 5 starsVivos Therapeutics scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingVivos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVivos Therapeutics has a consensus price target of $2.80, representing about 2,035.8% upside from its current price of $0.13.Amount of Analyst CoverageVivos Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Vivos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.24) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vivos Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vivos Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Vivos Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.06% of the float of Vivos Therapeutics has been sold short.Short Interest Ratio / Days to CoverVivos Therapeutics has a short interest ratio ("days to cover") of 0.36, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos Therapeutics has recently increased by 76.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivos Therapeutics does not currently pay a dividend.Dividend GrowthVivos Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentVivos Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vivos Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for VVOS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows4 people have added Vivos Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.10% of the stock of Vivos Therapeutics is held by insiders.Percentage Held by Institutions26.35% of the stock of Vivos Therapeutics is held by institutions.Read more about Vivos Therapeutics' insider trading history. Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VVOS Stock News HeadlinesVivos Therapeutics Strikes $12M Stock Deal For SOD Sciences Stake And Test RightsOctober 15 at 7:47 PM | rttnews.comVivos Therapeutics Announces Agreement to Acquire Stake in SOD Sciences and Co-Own Pseudohypoxia TestOctober 15 at 8:51 AM | quiverquant.comQTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 17 at 1:00 AM | Porter & Company (Ad)Vivos Therapeutics targets $3.6 million in annual cost reductions as revenue growth initiatives accelerateSeptember 29, 2026 | msn.comVivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth InitiativesSeptember 29, 2026 | globenewswire.comVivos Therapeutics Announces Material Debt ReductionSeptember 8, 2026 | globenewswire.comVivos Therapeutics Advances South Florida Sleep Center With South Palm Cardiovascular PartnershipAugust 28, 2026 | rttnews.comVivos Therapeutics Announces Definitive Agreements With South Palm Cardiovascular Associates to Launch South Florida Sleep & Airway Medicine CenterAugust 28, 2026 | quiverquant.comQSee More Headlines VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed this year? Vivos Therapeutics' stock was trading at $2.03 at the beginning of 2026. Since then, VVOS shares have decreased by 93.5% and is now trading at $0.1311. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its earnings results on Friday, August, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.10. The company had revenue of $5.15 million for the quarter, compared to the consensus estimate of $5.63 million. Vivos Therapeutics had a negative trailing twelve-month return on equity of 2,325.64% and a negative net margin of 122.00%. Read the conference call transcript. When did Vivos Therapeutics' stock split? Vivos Therapeutics's stock reverse split before market open on Friday, October 27th 2023.The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $21 million in an initial public offering on Thursday, December 10th 2020. The company issued 3,500,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vivos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Advanced Micro Devices (AMD), SoFi Technologies (SOFI), Tesla (TSLA), Alibaba Group (BABA), BigBear.ai (BBAI), Chevron (CVX) and Johnson & Johnson (JNJ). Company Calendar Last Earnings8/14/2026Today10/17/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VVOS's financial health is in the Red zone, according to TradeSmith. VVOS has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:VVOS CIK1716166 Webwww.vivos.com Phone866-908-4867FaxN/AEmployees268Year Founded2013Price Target and Rating Average Price Target for Vivos Therapeutics$2.80 High Price Target$3.10 Low Price Target$2.50 Potential Upside/Downside+2,035.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.17 million Net Margins-122.00% Pretax Margin-122.61% Return on Equity-2,325.64% Return on Assets-102.01% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual Sales$17.44 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.16) per share Price / Book-0.82Miscellaneous Outstanding Shares13,900,000Free Float13,603,000Market Cap$1.82 million OptionableOptionable Beta6.11 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:VVOS) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
